Molecular Partners AG (MOLN) stock

MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30

$3.09+0.00 (0.00%)

Close on Nov 11, 2026Market cap $124.76MP/E –Yield –

Molecular Partners ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -CHF 55.98M. The highest annual figure on record is CHF 119.00M in fiscal 2022.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-CHF 55.98M	–
FY2024	Dec 31, 2024	-CHF 58.85M	–
FY2023	Dec 31, 2023	-CHF 58.69M	-149.3%
FY2022	Dec 31, 2022	CHF 119.00M	–
FY2021	Dec 31, 2021	-CHF 60.85M	–
FY2020	Dec 31, 2020	-CHF 55.44M	–
FY2019	Dec 31, 2019	-CHF 34.19M	–

Parsed from the XBRL in Molecular Partners's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MOLN.

Revenue growth-100.0% · median -38.4%

Advertisement
300 × 250

See a number that looks wrong?